A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants
Latest Information Update: 01 Jul 2026
At a glance
- Drugs VCT 220 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Corxel Pharmaceuticals
Most Recent Events
- 23 Jun 2026 According to a Corxel Pharmaceuticals media release, Primary endpoint (Percentage change in body weight from baseline) has been met.
- 23 Jun 2026 Results presented in the Corxel Pharmaceuticals Media Release
- 28 May 2026 Status changed from active, no longer recruiting to completed.